In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes
about
Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesCanakinumabTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesRegulation of inflammasome signalingCurrent concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant dataVisualization and communication of pharmacometric models with berkeley madonnaAssessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage PredictionsSafety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studiesConstitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1betaWhy not treat human cancer with interleukin-1 blockade?Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis.Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion.Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammationMRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromesIL-1 blockade in autoinflammatory syndromes.Caspase functions in cell death and disease.Caspase-1: the inflammasome and beyond.Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis.Inducible HSP70 antagonizes IL-1β cytocidal effects through inhibiting NF-kB activation via destabilizing TAK1 in HeLa cells.Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome.NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells.From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.Chronic urticaria and arthritis with polyclonal IgA: rapid response and clinical remission with interleukin 1 blockade.An expanding role for interleukin-1 blockade from gout to cancer.Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatmentAutoinflammation: translating mechanism to therapy.Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)Therapy of autoinflammatory syndromes.Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal studyChronic inflammation in cancer development.IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study.NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasomePharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibodyBridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.
P2860
Q24606766-4F82B148-5A4B-460A-A6B6-D4C0116CD175Q24642193-9C12E577-8735-471B-A838-7B8A6791AE26Q26799747-B3702693-8A08-41AA-B575-53D4CF1D3C3FQ26996605-C29975C9-0AD0-4785-A9FD-8D54A01EFAE4Q27693189-D58CF3C0-D994-431D-AE60-84AE8573543EQ28742740-8C9E8954-1CC3-40BC-BCC2-90EE41C81ACAQ29584444-78B22467-97D0-4145-84DA-FB646EC83FB6Q31138430-FD9761EE-BF0B-4FF2-B172-D248E5ACD09AQ33661359-FBB38CF5-B03A-4B75-A7C8-D30F67FF8DE8Q33673719-4C7CCB50-7667-42F5-B266-EE81B61799BBQ33833871-77C47069-DB8B-4C00-AA95-1749F5DFF275Q33945041-8BB123AC-8C11-4183-892B-37492F928973Q33967100-84C7822E-6AC7-47E4-8B5F-A26B62C8BEA9Q34006421-FDA85A99-6893-43E3-85AD-F6A8A42515E4Q34167205-F6BC12E9-4A2D-45FD-BF98-A7789BB38851Q34240472-A701A0CF-F433-47E3-8092-9F8C54746E6AQ34262561-611FB70A-C148-499A-BEE6-5E35A348CD08Q34336335-584C14DD-FBE8-460F-B633-F5BE1D561703Q34344861-1C12E50C-F0CE-4549-A9F8-DAEE8B82FC13Q34431953-1C0D3DD2-9756-4AFA-B76D-092971DBF633Q34489840-93ABEAA9-E3F5-40E6-A57D-F6A65A2A4FC1Q34490968-B23907E6-EB9B-4AE4-9DDA-9653F8C75E36Q34544560-FEC74174-49A3-4A08-BA72-60E53F346505Q34635020-E13C9C90-942A-4D6D-A0B6-E4DA8B6970FAQ34764912-3BC65845-87FF-4570-9B94-058E38C039B2Q34901024-7236AD3F-2E12-48DB-BA09-69B3CE7BD1E1Q35008810-6AC3F605-B1D9-48B9-9262-011C7691FF30Q35219001-565E1C33-8372-43EE-97C2-F52152832DC5Q35535362-0DE580CC-B09E-4D64-9116-929D723A6AD0Q35558406-8999E69A-58E9-45CB-A36F-6E2928DF30D6Q35620372-8D265E6C-B15B-4361-BEDD-E0437E27B91FQ35868028-A2FD25F4-DF92-4C18-ABFB-3C666EF0607DQ35907804-14AB5281-3561-4796-9B26-196C3A73F631Q35928265-9DAEF04A-8707-47CA-82E4-CD703C680C23Q35996041-F170E546-A35B-4A5E-8C85-5AA5A3DEAD9EQ36213735-9E4CB60B-7D3F-4E11-836E-71C002F88CBBQ36303771-C7EA3AB8-36CA-42EE-88AD-E1F37C6E98E2Q36637240-CC2D1398-63C9-4ADA-A99B-EF7DB01E16E9Q36644667-2A3E993E-8689-46E5-8FF5-80A67B3D1D52Q36702456-E5916BC1-E2F2-41F3-BA35-8F649C128762
P2860
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo regulation of interleu ...... -associated periodic syndromes
@en
In vivo regulation of interleu ...... associated periodic syndromes.
@nl
type
label
In vivo regulation of interleu ...... -associated periodic syndromes
@en
In vivo regulation of interleu ...... associated periodic syndromes.
@nl
prefLabel
In vivo regulation of interleu ...... -associated periodic syndromes
@en
In vivo regulation of interleu ...... associated periodic syndromes.
@nl
P2093
P2860
P356
P1476
In vivo regulation of interleu ...... -associated periodic syndromes
@en
P2093
Christiane Rordorf
Helmut Wittkowski
Kieron Leslie
Nicole Hartmann
Philip N Hawkins
Sandra Daniela Felix
Sheril Madhoo
Sophie Bosset
Stephan Bek
Thomas Jung
P2860
P304
P356
10.1084/JEM.20082481
P407
P577
2009-04-13T00:00:00Z